Report cover image

Calcium Channel Blockers Market by Drug Class (Benzodiazepine, Dihydropyridine, Phenylalkylamine), End User (Homecare, Hospitals, Specialty Clinics), Distribution Channel - Global Forecast 2023-2030

Publisher 360iResearch
Published Oct 05, 2023
Length 185 Pages
SKU # IRE18313608

Description

Calcium Channel Blockers Market by Drug Class (Benzodiazepine, Dihydropyridine, Phenylalkylamine), End User (Homecare, Hospitals, Specialty Clinics), Distribution Channel - Global Forecast 2023-2030


The Calcium Channel Blockers Market is projected to reach USD 20.64 billion by 2030 from USD 12.82 billion in 2022, at a CAGR of 6.12% during the forecast period.

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Calcium Channel Blockers Market.
  • Based on Drug Class, market is studied across Benzodiazepine, Dihydropyridine, and Phenylalkylamine. The Phenylalkylamine is projected to witness significant market share during forecast period.
  • Based on End User, market is studied across Homecare, Hospitals, and Specialty Clinics. The Homecare is projected to witness significant market share during forecast period.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. The Online Pharmacy is projected to witness significant market share during forecast period.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.
Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Calcium Channel Blockers Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Calcium Channel Blockers Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Calcium Channel Blockers Market, highlighting leading vendors and their innovative profiles. These include Apotex Inc., Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Cadila Pharmaceuticals Limited, Daiichi Sankyo Company, Limited, Dr. Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals U.S. Inc., Hikma Pharmaceuticals PLC, INTAS PHARMACEUTICALS LTD., Kyowa Kirin Co., Ltd., Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, OTSUKA PHARMACEUTICAL CO., LTD., Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

The report offers valuable insights on the following aspects:
  1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
  2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
  3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
  4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
  5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
  1. What is the market size and forecast for the Calcium Channel Blockers Market?
  2. Which products, segments, applications, and areas hold the highest investment potential in the Calcium Channel Blockers Market?
  3. What is the competitive strategic window for identifying opportunities in the Calcium Channel Blockers Market?
  4. What are the latest technology trends and regulatory frameworks in the Calcium Channel Blockers Market?
  5. What is the market share of the leading vendors in the Calcium Channel Blockers Market?
  6. Which modes and strategic moves are suitable for entering the Calcium Channel Blockers Market?


Note: PDF & Excel + Online Access - 1 Year

Table of Contents

185 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Calcium Channel Blockers Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidences of low blood pressure worldwide
5.1.1.2. Inclination toward early diagnosis and treatment of diseases
5.1.1.3. Increasing awareness regarding low blood pressure treatments
5.1.2. Restraints
5.1.2.1. Product recall and volatility in raw material cost
5.1.3. Opportunities
5.1.3.1. Introduction of new generation calcium channel blockers
5.1.3.2. Clinical trials to test the efficacy of calcium channel blockers
5.1.4. Challenges
5.1.4.1. Adverse effects associated with calcium channel blockers
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Calcium Channel Blockers Market, by Drug Class
6.1. Introduction
6.2. Benzodiazepine
6.3. Dihydropyridine
6.4. Phenylalkylamine
7. Calcium Channel Blockers Market, by End User
7.1. Introduction
7.2. Homecare
7.3. Hospitals
7.4. Specialty Clinics
8. Calcium Channel Blockers Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacy
8.3. Online Pharmacy
8.4. Retail Pharmacy
9. Americas Calcium Channel Blockers Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Calcium Channel Blockers Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Calcium Channel Blockers Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Apotex Inc.
13.1.2. Astellas Pharma Inc.
13.1.3. AstraZeneca PLC
13.1.4. Bausch Health Companies Inc.
13.1.5. Bayer AG
13.1.6. Boehringer Ingelheim International GmbH
13.1.7. Bristol Myers Squibb Company
13.1.8. Cadila Pharmaceuticals Limited
13.1.9. Daiichi Sankyo Company, Limited
13.1.10. Dr. Reddy’s Laboratories Ltd.
13.1.11. Glenmark Pharmaceuticals U.S. Inc.
13.1.12. Hikma Pharmaceuticals PLC
13.1.13. INTAS PHARMACEUTICALS LTD.
13.1.14. Kyowa Kirin Co., Ltd.
13.1.15. Lupin Pharmaceuticals, Inc.
13.1.16. Merck & Co., Inc.
13.1.17. Novartis AG
13.1.18. OTSUKA PHARMACEUTICAL CO., LTD.
13.1.19. Pfizer Inc.
13.1.20. Sanofi S.A.
13.1.21. Sun Pharmaceutical Industries Ltd.
13.1.22. Takeda Pharmaceutical Company Limited
13.1.23. Teva Pharmaceutical Industries Ltd.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us